Skip to main content
All lobbying filings

EMD SERONO, INC.

Lobbying for EMD SERONO INC

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Expenses
$700,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 10

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 7
Copyright/Patent/Trademark

General discussions related to Biopharmaceutical innovation and patent policy issues

Trade (domestic/foreign)

Discussions related to tariffs and trade - Section 232 and Section 301 Discussions related to clinical minerals access

Health Issues

P.L. 119-21 (H.R. 1): One Big Beautiful Bill Act; provisions related to Title VII, Subtitle B H.R. 946: Orphan CURES Act; all provisions H.R. 2214: DRUG Act; all provisions H.R. 4317: PBM Reform Act of 2025; all provisions H.R. 6703: Lower Health Care Premiums for All Americans Act; provisions related to Pharmacy Benefit Management (PBM) S. 864: HELP Copays Act; all provisions S. 882: Patients Before Middlemen Act; all provisions S. 891: Bipartisan Health Care Act; provisions related to Titles I, II, VIII, and IX S. 1862: Orphan CURES Act; all provisions S. 3345: PBM Price Transparency and Accountability Act; all provisions Executive Order: Expanding Access to In Vitro Fertilization; all provisions of the order Executive Order: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; all provisions of the order General discussions related to Pharmacy Benefit Manager (PBM) policy issues General discussions related to Healthcare supply chain policy issues General discussions related to Drug cost and pricing policy issues General discussions related to caregiving support and awareness policy issues

Medicare/Medicaid

P.L. 119-21 (H.R. 1): One Big Beautiful Bill Act; relating to Title VII, Subtitle B H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.; all provisions S. 832: EPIC Act of 2025; all provisions S. 891: Bipartisan Health Care Act; provisions related to Titles I, II, VIII, and IX General discussions related to Drug cost and pricing policy issues

Pharmacy

H.R.5256: 340B ACCESS Act; all provisions General discussions related to Drug cost and pricing policy issues General discussions related to Healthcare supply chain policy issues General discussions related to 340B Drug Pricing Program policy issues

Veterans

H.R. 220: Veterans Infertility Treatment Act of 2025; all provisions

Defense

H.R. 3838: Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; provisions related to Military access to infertility care H.R. 6797: Bipartisan IVF for Military Families Act; all provisions H.R. 8800: National Defense Authorization Act for Fiscal Year 2027; provisions related to Military access to infertility care S. 1071: National Defense Authorization Act for Fiscal Year 2026; provisions related to Military access to infertility care S. 2296: National Defense Authorization Act for Fiscal Year 2026; provisions related to Military access to infertility care Discussions related to Military access to infertility care

 Bills named in this filing 19
  • H.R. 1
    One Big Beautiful Bill Act
  • H.R. 946
    ORPHAN Cures Act
  • H.R. 2214
    DRUG Act
  • H.R. 4317
    PBM Reform Act of 2025
  • H.R. 6703
    Lower Health Care Premiums for All Americans Act
  • S. 864
    HELP Copays Act
  • S. 882
    Patients Before Middlemen Act
  • S. 891
    Bipartisan Health Care Act
  • S. 1862
    ORPHAN Cures Act
  • S. 3345
    PBM Price Transparency and Accountability Act
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • S. 832
    EPIC Act of 2025
  • H.R. 5256
    340B ACCESS Act
  • H.R. 220
    Veterans Infertility Treatment Act of 2025
  • H.R. 3838
    Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
  • H.R. 6797
    Bipartisan IVF for Military Families Act
  • H.R. 8800
    National Defense Authorization Act for Fiscal Year 2027
  • S. 1071
    National Defense Authorization Act for Fiscal Year 2026
  • S. 2296
    National Defense Authorization Act for Fiscal Year 2026
 Foreign interests disclosed 1

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

  • MERCK PTE. LTD.
    Singapore · Ascent 11822 · owns 0% of the client · contributed $10,000

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem